Posts

Moderna’s COVID vaccine sales power a Q3 revenue beat

on
Moderna reported Q3 2026 revenue of $1.31 billion, up 29% year over year and well above analysts’ estimates of roughly $885–$890 million. The main driver was stronger COVID-19 vaccine sales in international markets, alongside deliveries under long-term government partnerships. Revenue was $780 million in the U.S. and $533 million internationally. The company swung to a $162 million profit from a $200 million loss a year earlier, reporting earnings of 38 cents per share against forecasts for a loss. Moderna raised its 2026 revenue-growth outlook to 15%–25%, from its prior forecast of growth of up to 10%. Sources: Moderna (MRNA) earnings Q3 2026 Moderna Lifts Outlook, Swings to 3Q Profit Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher Moderna's COVID vaccine carries stellar Q3 revenue beat sec-gov-archives-edgar-data-1682852-000168285226000194-exhibit9912026q3pressrelea-htm What Moderna (MRNA) Said on Its ...

Chai Discovery adds Roche to its AI drug-discovery partnerships

on

FDA expands J&J’s Rybrevant Faspro beyond lung cancer

on

Novartis reports seven newly disclosed tumor cases among Zolgensma patients

on

GeneDx and Mirum launch no-cost genetic testing programs

on

Inovia Bio launches InovaMine for clinical data analysis and drug development

on

AstraZeneca reportedly offers about $10B for Rhythm

on

Evommune licenses Hinova’s VAV1 drug candidate in deal worth up to $1.1 billion

on

RASONQUE brings in nearly $198 million in its first five weeks

on

Minghui licenses Japan rights to TED drug for $110M upfront

on

Ultragenyx to cut about 20% of staff and discontinue Wilson disease gene therapy

on

Boehringer Ingelheim and Sino announce potential $7B-plus cancer-drug deal

on

T-Therapeutics raises $133 million to advance cancer and autoimmune therapies

on